Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00743938 | A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC | PHASE2 | COMPLETED | 141 | — | — | Mar 1, 2009 | Jun 1, 2012 | Oct 12, 2015 | 30 | United States, Argentina +6 |
| Arm | Type | Description |
|---|---|---|
| A1 | EXPERIMENTAL | - |
| B2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-690514 | DRUG | Tablets, Oral, 200 mg, once daily, Until disease progression or toxicity |
| Erlotinib | DRUG | Capsules, Oral, 150 mg, once daily, Until disease progression or toxicity |
Inclusion Criteria: * ECOG PS of 0 or 1 * Histologically confirmed NSCLC * Adequate amount of tumor (archived or fresh) for biomarker evaluation * Received one to two regimens of chemotherapy (with at least one platinum-containing) * Serum creatinine of less than 1.0 mg/dL or a 24 hour creatinine c...